Jorge Castillo

Clinical Director, Bing Center for Waldenstrom Macroglobulinemia

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (28)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Approximately 20% of patients with Waldenström macroglobulinemia (WM) report family history (FH) of hematologic malignancies. However, the impact of FH on patient outcomes remains unclear. We included 1000 patients with WM to determine the relationship between FH, characteristics, complications, and treatment outcomes. Data collected included clinical features at diagnosis, complications (Bing-Neel syndrome [BNS], aggressive transformation, AL [light chain] amyloidosis, and neuropathy), FH cluster (WM [WM-FH], other B-cell FH [B-FH], non–B-cell FH [NON–B-FH], and sporadic [NO-FH]), and treatment outcomes. Logistic regression models were fitted to estimate the odds of complications. Time-to-event outcomes were assessed using the Kaplan-Meier method, and differences between groups evaluated using the log-rank test. Proportional hazards Cox regression models were fitted to determine the impact of WM-FH on time to first treatment (TTFT), overall survival (OS), and survival after first treatment initiation (SAFTI). The NO-FH group was the reference group for the regression analyses. The median follow-up time from diagnosis was 13 years. There were more women in the WM-FH than in the NO-FH group (50% vs 34%; P< .01). In multivariate logistic regression analysis, WM-FH was associated with higher odds of BNS (odds ratio [OR], 3.90; P = .005) and lower odds of neuropathy (OR, 0.49; P = .03) than NO-FH. The median TTFT was 0.7 years, OS was 23 years, and SAFTI was 20.5 years for all patients. In multivariate Cox regression analyses, WM-FH did not affect TTFT, SAFTI, or OS. Our study suggests higher odds of BNS and lower odds of neuropathy in patients with WM-FH but no impact of WM-FH on TTFT, OS, or SAFTI.

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Venetoclax is highly active in previously treated Waldenström macroglobulinemia (WM). However, data on the long-term durability and retreatment with venetoclax remain limited. Herein, we present an update of a prospective clinical trial of finite-duration venetoclax on 32 previously treated patients with WM. With a median follow-up of 81 months, 23 patients (72%) had disease progression, 17 (53%) began a new treatment, and 3 (9%) had died. The median progression-free survival (PFS) was 36 months, and the median treatment-free survival (TFS) was 43 months. PFS and TFS were superior in patients who attained at least a partial response to therapy. CXCR4 mutations or previous Bruton tyrosine kinase inhibitor exposure did not impact these outcomes. Of the 17 patients who started a new therapy after completion of venetoclax therapy, 9 were retreated with venetoclax alone or in combination with other treatments (3 attained a very good partial response, 4 attained a partial response, 1 had stable disease, and 1 did not respond). No BCL2 G101V mutations were detected in 52 CD19-selected bone marrow samples from 27 patients during treatment. Venetoclax induced durable responses in WM, thereby enabling retreatment in patients who progressed after completing therapy without the emergence of BCL2 G101V mutations. This trial was registered at www.ClinicalTrials.gov as #NCT02677324.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (32)

Simone FERRERO

University of Turin

ITALY
View details

sairah ahmed

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Stefan Barta

Academic Clinician Associate Professor

University of Pennsylvania

UNITED STATES
View details

Shaji Kumar

Medical College of Wisconsin

UNITED STATES
View details

Mehdi Hamadani

-

UNITED STATES
View details

Ariela Noy

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Constantine S. Tam

-

AUSTRALIA
View details

Camille V Edwards

Assistant Professor of Medicine

Boston University School of Medicine

UNITED STATES
View details

Peter Riedell

University of Chicago

UNITED STATES
View details

Steven Treon

Professor

Harvard Medical School

UNITED STATES
View details

Luis Malpica

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Julio Chavez

Associate Professor

Moffitt Cancer Center

UNITED STATES
View details

Jorge Florindez

Johns Hopkins University

UNITED STATES
View details

Adam Olszewski

Associate Professor of Medicine

Rhode Island Hospital

UNITED STATES
View details

Judith Trotman

Head of Department

Concord Repatriation General Hospital

AUSTRALIA
View details

Sebastian Grosicki

Head of Department, MD PhD, Ass. Prof

Medical University of Silesia

POLAND
View details

Morie Gertz

Mayo Clinic

UNITED STATES
View details

Shirong Liu

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Alain Delmer

Professor of Hematology

-

FRANCE
View details

Angela Dispenzieri

Professor / Consultant

Mayo Clinic Minnesota

UNITED STATES
View details

Stephen Opat

Monash Health

AUSTRALIA
View details

Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Carlos Fernandez de Larrea Rodriguez

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

SPAIN
View details

Michele Bibas

Chief of Hematology Service

-

ITALY
View details

Ramón García-Sanz

Profesor Titular de Medicina / Hematología

Universidad Complutense de Madrid

SPAIN
View details

Ranjana Advani

Saul A. Rosenberg Professor of Lymphoma

-

UNITED STATES
View details

Monique C. Minnema

-

NETHERLANDS
View details

Tanya Siddiqi

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details

Roch Houot

university hospital of Rennes

FRANCE
View details

Jonas Paludo

Assistant Professor of Medicine and Oncology

Mayo Clinic

UNITED STATES
View details

Timothy Voorhees

Associate Professor of Clinical Internal Medicine

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute

SPAIN
View details